Enveric Biosciences Executes Reverse Stock Split and Announces Patent Milestone

0.7 min readPublished On: February 5th, 2025By

LOS ANGELES- Enveric Biosciences, Inc.  recently implemented a 1-for-15 reverse stock split, effective January 29, 2025, to comply with Nasdaq’s minimum bid price requirement. Following the split, the company conducted a public offering, raising $5 million through the issuance of 1.67 million shares priced at $3 each, accompanied by Series A and B warrants. This financing round led to a significant decline in the company’s stock price, with shares dropping over 40% in pre-market trading on January 31, 2025.

In parallel, Enveric received a Notice of Allowance from the U.S. Patent and Trademark Office for its lead neuroplastogenic compound, EB-003. This patent covers the composition of matter and methods of use for EB-003, which is under development for treatment-resistant depression and anxiety. The company highlights that EB-003 aims to promote neuroplasticity without inducing hallucinations, potentially allowing for treatment without the need for healthcare professional supervision during administration.

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!